Doris A Taylor

List of Publications by Citations

Source: https://exaly.com/author-pdf/7196578/doris-a-taylor-publications-by-citations.pdf
Version: 2024-04-28

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124 papers	8,793 citations	38 h-index	93 g-index
141 ext. papers	9,839 ext. citations	8.5 avg, IF	5.74 L-index

#	Paper	IF	Citations
124	Perfusion-decellularized matrix: using natureß platform to engineer a bioartificial heart. *Nature Medicine*, **2008**, 14, 213-21	50.5	2047
123	Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. *Nature Medicine*, **1998**, 4, 929-33	50.5	946
122	Whole-organ tissue engineering: decellularization and recellularization of three-dimensional matrix scaffolds. *Annual Review of Biomedical Engineering*, **2011**, 13, 27-53	12	755
121	Aging, progenitor cell exhaustion, and atherosclerosis. *Circulation*, **2003**, 108, 457-63	16.7	597
120	Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. *JAMA - Journal of the American Medical Association*, **2012**, 307, 1717-26	27.4	338
119	Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. *JAMA - Journal of the American Medical Association*, **2011**, 306, 2110-9	27.4	314
118	Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. *JAMA - Journal of the American Medical Association*, **2012**, 308, 2380-9	27.4	295
117	Decellularized matrices in regenerative medicine. *Acta Biomaterialia*, **2018**, 74, 74-89	10.8	155
116	Comparison of benefits on myocardial performance of cellular cardiomyoplasty with skeletal myoblasts and fibroblasts. *Cell Transplantation*, **2000**, 9, 359-68	4	150
115	Circulating endothelial progenitor cells predict coronary artery disease severity. *American Heart Journal*, **2006**, 152, 190-5	4.9	146
114	Acellular human heart matrix: A critical step toward whole heart grafts. *Biomaterials*, **2015**, 61, 279-89	15.6	124
113	Engineering skeletal myoblasts: roles of three-dimensional culture and electrical stimulation. *American Journal of Physiology - Heart and Circulatory Physiology*, **2005**, 288, H1620-6	5.2	123
112	Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. *Circulation*, **2014**, 129, 2287-96	16.7	113
111	Optimizing recellularization of whole decellularized heart extracellular matrix. *PLoS ONE*, **2014**, 9, e90406	3.7	105
110	Intracardiac transplantation of skeletal myoblasts yields two populations of striated cells in situ. *Annals of Thoracic Surgery*, **1999**, 67, 124-9	2.7	103
109	Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium. *Journal of Heart and Lung Transplantation*, **1999**, 18, 1173-80	5.8	100
108	Improved efficacy of stem cell labeling for magnetic resonance imaging studies by the use of cationic liposomes. *Cell Transplantation*, **2003**, 12, 743-56	4	99

107	Global position paper on cardiovascular regenerative medicine. *European Heart Journal*, **2017**, 38, 2532-2546	9.5	90
106	Cardiac chimerism as a mechanism for self-repair: does it happen and if so to what degree?. *Circulation*, **2002**, 106, 2-4	16.7	82
105	Automated decellularization of intact, human-sized lungs for tissue engineering. *Tissue Engineering - Part C: Methods*, **2015**, 21, 94-103	2.9	76
104	Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit Cardiac Stem Cells As Regenerative Therapy for Heart Failure). *Circulation Research*, **2018**, 122, 1703-1715	15.7	72
103	Transplantation of mesenchymal cells rejuvenated by the overexpression of telomerase and myocardin promotes revascularization and tissue repair in a murine model of hindlimb ischemia. *Circulation Research*, **2013**, 113, 902-14	15.7	72
102	Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. *American Heart Journal*, **2009**, 158, 356-63	4.9	66
101	Cellular cardiomyoplasty improves diastolic properties of injured heart. *Journal of Surgical Research*, **1999**, 85, 234-42	2.5	63
100	An epicardial bioelectronic patch made from soft rubbery materials and capable of spatiotemporal mapping of electrophysiological activity. *Nature Electronics*, **2020**, 3, 775-784	28.4	62
99	Autologous skeletal myoblast transplantation improved hemodynamics and left ventricular function in chronic heart failure dogs. *Journal of Heart and Lung Transplantation*, **2005**, 24, 1940-9	5.8	59
98	Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes. *Circulation Research*, **2014**, 115, 867-74	15.7	50
97	Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial. *Circulation Research*, **2015**, 116, 99-107	15.7	49
96	Experimental orthotopic transplantation of a tissue-engineered oesophagus in rats. *Nature Communications*, **2014**, 5, 3562	17.4	47
95	Fiber type-specific differential expression of angiogenic factors in response to chronic hindlimb ischemia. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H932-8	5.2	47
94	Comparison of intracardiac cell transplantation: autologous skeletal myoblasts versus bone marrow cells. *Circulation*, **2003**, 108 Suppl 1, II264-71	16.7	46
93	From stem cells and cadaveric matrix to engineered organs. *Current Opinion in Biotechnology*, **2009**, 20, 598-605	11.4	45
92	LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. *Texas Heart Institute Journal*, **2010**, 37, 412-20	0.8	45
91	Report of the National Heart, Lung, and Blood Institute Working Group on Sex Differences Research in Cardiovascular Disease: Scientific Questions and Challenges. *Hypertension*, **2016**, 67, 802-7	8.5	44
90	Mechanical changes in the rat right ventricle with decellularization. *Journal of Biomechanics*, **2012**, 45, 842-9	2.9	43

89	Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN). *Circulation*, **2013**, 127, 1630-5	16.7	38
88	Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design. *American Heart Journal*, **2010**, 160, 215-23	4.9	38
87	Sex-dependent attenuation of plaque growth after treatment with bone marrow mononuclear cells. *Circulation Research*, **2007**, 101, 1319-27	15.7	38
86	Myocardial commitment from human pluripotent stem cells: Rapid production of human heart grafts. *Biomaterials*, **2016**, 98, 64-78	15.6	37
85	TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis. *Circulation Research*, **2018**, 122, 479-488	15.7	36
84	Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network. *Circulation Research*, **2014**, 114, 1564-8	15.7	35
83	Building new hearts: a review of trends in cardiac tissue engineering. *American Journal of Transplantation*, **2014**, 14, 2448-59	8.7	35
82	Tracheal regeneration: evidence of bone marrow mesenchymal stem cell involvement. *Journal of Thoracic and Cardiovascular Surgery*, **2013**, 145, 1297-1304.e2	1.5	35
81	Endoventricular transplantation of allogenic skeletal myoblasts in a porcine model of myocardial infarction. *Journal of Endovascular Therapy*, **2002**, 9, 313-9	2.5	34
80	Bioengineering Hearts: Simple yet Complex. *Current Stem Cell Reports*, **2017**, 3, 35-44	1.8	33
79	Cell-based myocardial repair: how should we proceed?. *International Journal of Cardiology*, **2004**, 95 Suppl 1, S8-12	3.2	33
78	Cellular cardiomyoplasty with autologous skeletal myoblasts for ischemic heart disease and heart failure. *Current Controlled Trials in Cardiovascular Medicine*, **2001**, 2, 208-210		32
77	Inverted orientation improves decellularization of whole porcine hearts. *Acta Biomaterialia*, **2017**, 49, 181-191	10.8	31
76	Strategies and methods to study sex differences in cardiovascular structure and function: a guide for basic scientists. *Biology of Sex Differences*, **2011**, 2, 14	9.3	31
75	Orthotopic transplantation of a tissue engineered diaphragm in rats. *Biomaterials*, **2016**, 77, 320-35	15.6	30
74	Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells). *Circulation*, **2017**, 135, 1417-1428	16.7	29
73	Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1β and IL-6-Related Impairment of Bone Marrow Function. *Circulation Research*, **2017**, 120, 1947-1957	15.7	27
72	Atherosclerosis as a disease of failed endogenous repair. *Frontiers in Bioscience - Landmark*, **2008**, 13, 3621-36	2.8	27

71	Functional assessment of myoblast transplantation for cardiac repair with magnetic resonance imaging. *European Journal of Heart Failure*, **2005**, 7, 435-43	12.3	27
70	A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. *European Journal of Heart Failure*, **2021**, 23, 661-674	12.3	26
69	Maximizing Cardiac Repair: Should We Focus on the Cells or on the Matrix?. *Circulation Research*, **2017**, 120, 30-32	15.7	23
68	Building a Total Bioartificial Heart: Harnessing Nature to Overcome the Current Hurdles. *Artificial Organs*, **2018**, 42, 970-982	2.6	23
67	Cell therapy for heart failure--muscle, bone marrow, blood, and cardiac-derived stem cells. *Seminars in Thoracic and Cardiovascular Surgery*, **2005**, 17, 348-60	1.7	23
66	Intracardiac transplantation of a mixed population of bone marrow cells improves both regional systolic contractility and diastolic relaxation. *Journal of Heart and Lung Transplantation*, **2005**, 24, 205-14	5.8	23
65	Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial. *Cell Transplantation*, **2016**, 25, 1675-1687	4	23
64	An in vitro system to evaluate the effects of ischemia on survival of cells used for cell therapy. *Annals of Biomedical Engineering*, **2007**, 35, 1414-24	4.7	22
63	The ubiquitin-proteasome system: A potential therapeutic target for heart failure. *Journal of Heart and Lung Transplantation*, **2017**, 36, 708-714	5.8	21
62	Perspectives on Directions and Priorities for Future Preclinical Studies in Regenerative Medicine. *Circulation Research*, **2019**, 124, 938-951	15.7	20
61	The real estate of myoblast cardiac transplantation: negative remodeling is associated with location. *Journal of Heart and Lung Transplantation*, **2008**, 27, 116-23	5.8	20
60	Sex-Based Differences in Outcomes After Mitral Valve Surgery for Severe Ischemic Mitral Regurgitation: From the Cardiothoracic Surgical Trials Network. *JACC: Heart Failure*, **2019**, 7, 481-490	7.9	19
59	Recellularization of rat liver: An in vitro model for assessing human drug metabolism and liver biology. *PLoS ONE*, **2018**, 13, e0191892	3.7	18
58	Endoventricular Transplantation of Allogenic Skeletal Myoblasts in a Porcine Model of Myocardial Infarction. *Journal of Endovascular Therapy*, **2002**, 9, 313-319	2.5	18
57	Laminin as a Potent Substrate for Large-Scale Expansion of Human Induced Pluripotent Stem Cells in a Closed Cell Expansion System. *Stem Cells International*, **2019**, 2019, 9704945	5	16
56	Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale. *American Heart Journal*, **2011**, 162, 973-80	4.9	15
55	Video-assisted thoracoscopic transplantation of myoblasts into the heart. *Annals of Thoracic Surgery*, **2004**, 78, 303-7	2.7	15
54	Circulating Biomarkers to Identify Responders in Cardiac Cell therapy. *Scientific Reports*, **2017**, 7, 4419	4.9	14

53	Transplantation of skeletal myoblasts for cardiac repair. *Journal of Heart and Lung Transplantation*, **2004**, 23, 1217-27	5.8	14
52	Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial. *American Heart Journal*, **2016**, 179, 142-50	4.9	14
51	Robotic minimally invasive cell transplantation for heart failure. *Journal of Thoracic and Cardiovascular Surgery*, **2006**, 132, 170-3	1.5	12
50	From cardiac repair to cardiac regeneration--ready to translate?. *Expert Opinion on Biological Therapy*, **2006**, 6, 867-78	5.4	12
49	Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial. *JACC: CardioOncology*, **2020**, 2, 581-595	3.8	12
48	Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials. *Basic Research in Cardiology*, **2017**, 112, 3	11.8	11
47	Tissue-engineered human embryonic stem cell-containing cardiac patches: evaluating recellularization of decellularized matrix. *Journal of Tissue Engineering*, **2020**, 11, 2041731420921482	7.5	11
46	Whole Cardiac Tissue Bioscaffolds. *Advances in Experimental Medicine and Biology*, **2018**, 1098, 85-114	3.6	11
45	Data from acellular human heart matrix. *Data in Brief*, **2016**, 8, 211-9	1.2	10
44	Fundamentos de la terapia celular para el tratamiento de las enfermedades cardiovasculares: no hay una c□la adecuada para todo. *Revista Espanola De Cardiologia*, **2009**, 62, 1032-1044	1.5	9
43	Regulation of carbohydrate and fatty acid utilization by L-carnitine during cardiac development and hypoxia. *Molecular and Cellular Biochemistry*, **1998**, 180, 95-103	4.2	9
42	Cell therapy for left ventricular remodeling. *Current Heart Failure Reports*, **2007**, 4, 3-10	2.8	9
41	Effects of myocardial infarction on the distribution and transport of nutrients and oxygen in porcine myocardium. *Journal of Biomechanical Engineering*, **2012**, 134, 101005	2.1	8
40	Decellularization of Whole Human Heart Inside a Pressurized Pouch in an Inverted Orientation. *Journal of Visualized Experiments*, **2018**,	1.6	8
39	Optimized method for isolating highly purified and functional porcine aortic endothelial and smooth muscle cells. *Journal of Cellular Physiology*, **2017**, 232, 3139-3145	7	6
38	Systolic contraction within aneurysmal rabbit myocardium following transplantation of autologous skeletal myoblasts. *Journal of Surgical Research*, **2006**, 135, 202-8	2.5	6
37	Change the Laminin, Change the Cardiomyocyte: Improve Untreatable Heart Failure. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	5
36	The Future of Tissue Engineering in Heart Transplantation. *Texas Heart Institute Journal*, **2019**, 46, 73-74	0.8	4

35	Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarction. *American Heart Journal*, **2020**, 220, 155-175	4.9	4
34	A Path Forward for Regenerative Medicine. *Circulation Research*, **2018**, 123, 495-505	15.7	4
33	Leadless multisite pacing: A feasibility study using wireless power transfer based on Langendorff rodent heart models. *Journal of Cardiovascular Electrophysiology*, **2018**, 29, 1588-1593	2.7	4
32	Till truth makes all things plain: human hearts and stem cells. *Circulation Research*, **2014**, 115, 908-10	15.7	3
31	The basics of cell therapy to treat cardiovascular disease: one cell does not fit all. *Revista Espanola De Cardiologia (English Ed)*, **2009**, 62, 1032-44	0.7	3
30	Cues from human atrial extracellular matrix enrich the atrial differentiation of human induced pluripotent stem cell-derived cardiomyocytes. *Biomaterials Science*, **2021**, 9, 3737-3749	7.4	3
29	What will it take before a bioengineered heart will be implanted in patients?. *Current Opinion in Organ Transplantation*, **2018**, 23, 664-672	2.5	3
28	Premature atherosclerosis in premenopausal women: Does cytokine balance play a role?. *Medical Hypotheses*, **2017**, 109, 38-41	3.8	2
27	Building solutions for cardiovascular disease in women. *Texas Heart Institute Journal*, **2013**, 40, 285-7	0.8	2
26	Gelatin Promotes Cell Retention Within Decellularized Heart Extracellular Matrix Vasculature and Parenchyma. *Cellular and Molecular Bioengineering*, **2020**, 13, 633-645	3.9	2
25	Recommendations for Nomenclature and Definition Of Cell Products Intended for Human Cardiovascular Use. *Cardiovascular Research*, **2021**,	9.9	2
24	Response to letter to Editor "Comment on Unverted orientation improves decellularization of whole porcine heartsUby Lee et al.". *Acta Biomaterialia*, **2017**, 53, 645	10.8	1
23	Whole-heart scaffoldsHow to build a heart **2019**, 617-642		1
22	Tissue-engineered cardiovascular products **2020**, 1521-1536		1
21	Is in vivo remodeling necessary or sufficient for cellular repair of the heart?. *Annals of the New York Academy of Sciences*, **2002**, 961, 315-8	6.5	1
20	Cell therapy-a 21st century hope for treating cardiovascular disease-a five-year retrospective and predictive view. *The American Heart Hospital Journal*, **2011**, 9, E24-7		1
19	Recruiting for Acute Myocardial Infarction Cell Therapy Trials: Challenges and Best Practices for the CCTRN **2014**, 28, 71-77		1
18	Decellularization of whole hearts for cardiac regeneration **2020**, 291-310		1

17	Impaired therapeutic efficacy of bone marrow cells from post-myocardial infarction patients in the TIME and LateTIME clinical trials. *PLoS ONE*, **2020**, 15, e0237401	3.7	1
16	Organogenesis **2016**, 349-373		1
15	Cells for the treatment, prevention, and cure of cardiovascular disease. *Texas Heart Institute Journal*, **2009**, 36, 148-9	0.8	0
14	Characterization of perfusion decellularized whole animal body, isolated organs, and multi-organ systems for tissue engineering applications. *Physiological Reports*, **2021**, 9, e14817	2.6	0
13	Engineering Functional Vasculature in Decellularized Lungs Depends on Comprehensive Endothelial Cell Tropism. *Frontiers in Bioengineering and Biotechnology*, **2021**, 9, 727869	5.8	0
12	Peripheral Blood Biomarkers Associated With Improved Functional Outcome in Patients With Chronic Left Ventricular Dysfunction: A Biorepository Evaluation of the FOCUS-CCTRN Trial. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 698088	5.4	0
11	Analysis of sex-based differences in clinical and molecular responses to ischemia reperfusion after lung transplantation.. *Respiratory Research*, **2021**, 22, 318	7.3	0
10	Pedro Brugada and Peter Schwartz share the Lefoulon-Delalande Foundation Scientific Prize 2019. *European Heart Journal*, **2019**, 40, 2670	9.5	
9	Stem Cells and Liver Regeneration **2015**, 1429-1437		
8	Cell therapy: a 21st-century hope for treating cardiovascular disease--what do the next 5 years hold?. *The American Heart Hospital Journal*, **2006**, 4, 219-21		
7	A Porcine Model of Myocardial Infarction for Evaluation of Cell Transplantation **2006**, 231-238		
6	Myoblast Cell Transplantation: Preclinical Studies **2006**, 81-93		
5	Cardiac Cell Transplantation **2007**, 259-274		
4	Cell-Based Repair for Cardiovascular Regeneration and Neovascularization: What, Why, How, and Where Are We Going in the Next 5�0 Years? **2008**, 812-851		
3	Signature of Responders�essons from Clinical Samples **2016**, 445-460		
2	Sex-Based Differences in Autologous Cell Therapy Trials in Patients With Acute Myocardial Infarction: Subanalysis of the ACCRUE Database. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 664277	5.4	
1	Strategies for iPSC expansion: from feeder cells to laminin **2021**, 209-229		